The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 11, 2022

Filed:

Feb. 10, 2017
Applicant:

Autolus Limited, London, GB;

Inventors:

Martin Pulé, London, GB;

Shaun Cordoba, London, GB;

Simon Thomas, London, GB;

Shimobi Onuoha, London, GB;

Maria Stavrou, London, GB;

Assignee:

AUTOLUS LIMITED, London, GB;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/725 (2006.01); A61K 35/17 (2015.01); C07K 14/73 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); A61K 35/17 (2013.01); C07K 14/70514 (2013.01); C07K 16/2803 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/60 (2013.01);
Abstract

The present invention provides a chimeric antigen receptor (CAR) system comprising; (i) a receptor component comprising a antigen binding domain and a first binding domain; and (ii) a signalling component comprising a signalling domain and a second binding domain which binds the single domain binder of the first binding domain of the receptor component wherein either the first or second binding domains comprise a single domain binder, and wherein, binding of the first and second binding domains is disrupted by the presence of an agent, such that in the absence of the agent, the receptor component and the signalling component heterodimerize and binding of the antigen binding domain to antigen results in signalling through the signalling domain; whereas in the presence of the agent, the receptor component and the signalling component do not heterodimerize and binding of the antigen binding domain to antigen does not result in signalling through the signalling domain.


Find Patent Forward Citations

Loading…